About BARDA DRIVe
BARDA DRIVe is a company. It operates as a Professional Services. BARDA DRIVe offers products and services including TyPe (Therapeutic Efficacy through Predicting Treatment Response), IMMUNECHIP+, and Influenza Vaccine Innovation.
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Latest Funding Round
-
Investors
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of BARDA DRIVe
BARDA DRIVe offers a comprehensive portfolio of products and services, including TyPe (Therapeutic Efficacy through Predicting Treatment Response), IMMUNECHIP+, and Influenza Vaccine Innovation. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Patient stratification products are developed for therapeutic efficacy.
3D human tissue models are enhanced for drug development.
Effective influenza vaccines are developed for future pandemics.
Funding Insights of BARDA DRIVe
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investments & Acquisitions by BARDA DRIVe
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - BARDA DRIVe
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Barda Drive Comparisons
Competitors of BARDA DRIVe
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about BARDA DRIVe
What does BARDA DRIVe do?
Early-stage companies are supported by BARDA DRIVe for life-saving innovations in health security. Focus is placed on breakthrough devices and technologies to tackle major health threats. Programs such as therapeutic efficacy, vaccine delivery, and diagnostics are funded across various sectors. A network of accelerators is launched to streamline processes and support new technologies. The approach is modeled on entrepreneurial best practices to address health security challenges.
What products or services does BARDA DRIVe offer?
BARDA DRIVe offers TyPe (Therapeutic Efficacy through Predicting Treatment Response), IMMUNECHIP+, and Influenza Vaccine Innovation.